Citation: H. Fenner et R. Rau, Influence of gold versus methotrexate treatment on cytokine-profiles and markers of bone and cartilage destruction, Z RHEUMATOL, 60(3), 2001, pp. 174-176
Authors:
Woodworth, TG
Furst, DE
Strand, V
Kempeni, J
Fenner, H
Lau, CS
Miller, F
Day, R
Lipani, J
Brooks, P
Citation: Tg. Woodworth et al., Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies, J RHEUMATOL, 28(5), 2001, pp. 1163-1169
Citation: R. Rau et al., The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years, J RHEUMATOL, 27(11), 2000, pp. 2566-2575
Authors:
Brooks, P
Emery, P
Evans, JF
Fenner, H
Hawkey, CJ
Patrono, C
Smolen, J
Breeveld, F
Day, R
Dougados, M
Ehrich, EW
Gijon-Banos, J
Kvien, TK
Van Rijswijk, MH
Warner, T
Zeidler, H
Citation: P. Brooks et al., Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2, RHEUMATOLOG, 38(8), 1999, pp. 779-788